INTERVIEW: Code of Conduct Sets European Medtech Industry On The Front Foot
This article was originally published in Clinica
European medical device and diagnostics manufacturers have adopted a new common Code of Ethical Business Practice which will be implemented nationally as of 2017. Industry sees the code as part of efforts to set visibly high ethical standards and as a clear signal to other stakeholders of how seriously it takes stringent self-regulation. Clinica asked UK ABHI chairman Phil Kennedy what he hopes the initiative will achieve
You may also be interested in...
First of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: The UK IVD companies are soon to get new tools designed to make market access for innovations easier and more predictable. This is welcome news, given the backdrop of Brexit and the costly route to compliance to the new EU IVD Regulation compliance.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.